{
    "title": "Akero's drug meets main goal in NASH trial, shares surge 120%",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11208029/Akero-Therapeutics-lead-drug-meets-main-goal-NASH-trial-shares-jump.html",
    "date": "2022-09-13",
    "keywords": [
        "drug",
        "study",
        "liver",
        "mg",
        "leo",
        "treatment",
        "disease",
        "market",
        "latestage",
        "trial",
        "improvement",
        "nash",
        "week",
        "placebo",
        "arm",
        "company",
        "akero",
        "officer",
        "tuesday",
        "goal",
        "midstage",
        "type",
        "medicine",
        "jump",
        "companys",
        "efruxifermin",
        "steatohepatitis",
        "foundation",
        "ailment",
        "nordisk",
        "inc",
        "intercept",
        "year",
        "design",
        "chief",
        "development",
        "catriona",
        "conference",
        "call",
        "management",
        "pipeline",
        "madrigal",
        "dosage",
        "onestage",
        "scarring",
        "weightreduction",
        "dose",
        "adoption",
        "tim",
        "rolph",
        "reporting",
        "bengaluru",
        "editing",
        "dasgupta",
        "anil",
        "dsilva"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}